Return to homepagePandemic Pact

A Phase 2/3, Observer-blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covovax [Sars-cov-2 Recombinant Spike Protein Nanoparticle Vaccine (Sars-cov-2 Rs) With Matrix-m1™ Adjuvant] in IndianAdults

  • Funded by 360biolabs, Indian Council of Medical Research (ICMR), Novavax
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $996,127.4

  • Funder

    360biolabs, Indian Council of Medical Research (ICMR), Novavax

  • Principal Investigator

    Dr. Abhijit Vasantrao Kadam

  • Research Location

    India

  • Lead Research Institution

    ICMR-National AIDS Research Institute (ICMR-NARI)

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract